Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial.
Fujita K, Arai R, Shoji S, Saito R, Nomura M, Hotta T, Asahina H, Kawakami M, Nakachi I, Hasegawa Y, Okafuji K, Suzuki A, Miyanaga A, Sunaga N, Nagashima H, Ikeda N, Watanabe S, Nagai Y, Furuta M, Kage H, Arai D, Fukuhara T, Nakayama M, Morita S, Kobayashi K, Hagiwara K. Fujita K, et al. Among authors: miyanaga a. Cancer Sci. 2023 Aug;114(8):3342-3351. doi: 10.1111/cas.15831. Epub 2023 May 3. Cancer Sci. 2023. PMID: 37139543 Free PMC article.
Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
Masuda M, Chen WY, Miyanaga A, Nakamura Y, Kawasaki K, Sakuma T, Ono M, Chen CL, Honda K, Yamada T. Masuda M, et al. Among authors: miyanaga a. Mol Cell Proteomics. 2014 Jun;13(6):1429-38. doi: 10.1074/mcp.M113.033845. Epub 2014 Mar 18. Mol Cell Proteomics. 2014. PMID: 24643969 Free PMC article.
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A. Noro R, et al. Among authors: miyanaga a. Cancer Sci. 2010 Jun;101(6):1424-30. doi: 10.1111/j.1349-7006.2010.01559.x. Epub 2010 Mar 10. Cancer Sci. 2010. PMID: 20384633 Free article.
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A. Miyanaga A, et al. BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262. BMC Cancer. 2013. PMID: 23714228 Free PMC article.
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R, Kobayashi K, Usuki J, Yomota M, Nishitsuji M, Shimokawa T, Ando M, Hino M, Hagiwara K, Miyanaga A, Seike M, Kubota K, Gemma A; North East Japan Study group. Noro R, et al. Among authors: miyanaga a. Thorac Cancer. 2020 Jul;11(7):1876-1884. doi: 10.1111/1759-7714.13472. Epub 2020 May 18. Thorac Cancer. 2020. PMID: 32421226 Free PMC article. Clinical Trial.
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
Miyanaga A, Asahina H, Watanabe S, Shukuya T, Tsubata Y, Hosomi Y, Sugawara S, Maemondo M, Okano T, Morita S, Matsuyama K, Kobayashi K, Seike M. Miyanaga A, et al. Clin Lung Cancer. 2023 Jun;24(4):371-375. doi: 10.1016/j.cllc.2023.01.008. Epub 2023 Feb 1. Clin Lung Cancer. 2023. PMID: 36849264 Free article. Clinical Trial.
Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study).
Nakamura A, Yamaguchi O, Mori K, Miura K, Tamiya M, Oba T, Yanagitani N, Mizutani H, Ninomiya T, Kajiwara T, Ito K, Miyanaga A, Arai D, Kodama H, Kobayashi K, Kaira K. Nakamura A, et al. Among authors: miyanaga a. Eur J Cancer. 2023 May;184:62-72. doi: 10.1016/j.ejca.2023.01.025. Epub 2023 Feb 11. Eur J Cancer. 2023. PMID: 36905770
Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
Miura K, Yamaguchi O, Mori K, Nakamura A, Tamiya M, Oba T, Yanagitani N, Mizutani H, Ninomiya T, Kajiwara T, Ito K, Miyanaga A, Arai D, Kodama H, Kobayashi K, Kaira K. Miura K, et al. Among authors: miyanaga a. Sci Rep. 2024 Feb 15;14(1):3816. doi: 10.1038/s41598-024-54166-x. Sci Rep. 2024. PMID: 38360906 Free PMC article.
147 results